X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

KRTX

Closed

Karuna Therapeutics Inc

329.83
+0.09 (+0.03%)
Last Update: 18 Mar 2024 16:30:00
Yesterday: 329.74
Day's Range: 329.83 - 329.83
Send
When Written:
 
178.46
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies to treat neuropsychiatric disorders. The company is based in Boston, Massachusetts and was founded in 2009. Karuna Therapeutics is developing a pipeline of novel drug candidates that target the muscarinic acetylcholine receptor (mAChR) system, which is involved in regulating the activity of neurotransmitters in the brain.

Karuna Therapeutics' lead drug candidate is KarXT, which is being developed as a potential treatment for schizophrenia and other neuropsychiatric disorders. KarXT is a combination of xanomeline, an mAChR agonist, and trospium, an mAChR antagonist. The company has completed Phase 2 clinical trials of KarXT in patients with schizophrenia and is currently conducting Phase 2 clinical trials in patients with dementia-related psychosis.

Karuna Therapeutics has also developed a pipeline of other drug candidates that target the mAChR system, including KarNAc, which is being developed as a potential treatment for Alzheimer's disease and other neurodegenerative disorders. The company has partnerships with several academic institutions and pharmaceutical companies to advance its drug development programs.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X